Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxoprexin vs Paclitaxel with Carboplatin in Advanced NSCLC
NCT00243867Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- Nov 2005
- Primary completion
- Aug 2008
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel docosahexaenoic acid in non-small cell lung cancer (NSCLC) (2 arms), sponsored by American Regent, Inc. Primary endpoint: Overall Survival at 12 months. Started Nov 2005; status: completed.
02
Drugs
paclitaxel docosahexaenoic acid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00243867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243867.